Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
Harris CM, Ericsson AM, Argiriadi MA, Barberis C, Borhani DW, Burchat A, Calderwood DJ, Cunha GA, Dixon RW, Frank KE, Johnson EF, Kamens J, Kwak S, Li B, Mullen KD, Perron DC, Wang L, Wishart N, Wu X, Zhang X, Zmetra TR, Talanian RV. Harris CM, et al. Among authors: talanian rv. Bioorg Med Chem Lett. 2010 Jan 1;20(1):334-7. doi: 10.1016/j.bmcl.2009.10.103. Epub 2009 Oct 29. Bioorg Med Chem Lett. 2010. PMID: 19926477
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study.
Argiriadi MA, Sousa S, Banach D, Marcotte D, Xiang T, Tomlinson MJ, Demers M, Harris C, Kwak S, Hardman J, Pietras M, Quinn L, DiMauro J, Ni B, Mankovich J, Borhani DW, Talanian RV, Sadhukhan R. Argiriadi MA, et al. Among authors: talanian rv. BMC Struct Biol. 2009 Mar 18;9:16. doi: 10.1186/1472-6807-9-16. BMC Struct Biol. 2009. PMID: 19296855 Free PMC article.
2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
Argiriadi MA, Ericsson AM, Harris CM, Banach DL, Borhani DW, Calderwood DJ, Demers MD, Dimauro J, Dixon RW, Hardman J, Kwak S, Li B, Mankovich JA, Marcotte D, Mullen KD, Ni B, Pietras M, Sadhukhan R, Sousa S, Tomlinson MJ, Wang L, Xiang T, Talanian RV. Argiriadi MA, et al. Among authors: talanian rv. Bioorg Med Chem Lett. 2010 Jan 1;20(1):330-3. doi: 10.1016/j.bmcl.2009.10.102. Epub 2009 Oct 29. Bioorg Med Chem Lett. 2010. PMID: 19919896
Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor.
Argiriadi MA, Goedken ER, Banach D, Borhani DW, Burchat A, Dixon RW, Marcotte D, Overmeyer G, Pivorunas V, Sadhukhan R, Sousa S, Moore NS, Tomlinson M, Voss J, Wang L, Wishart N, Woller K, Talanian RV. Argiriadi MA, et al. Among authors: talanian rv. BMC Struct Biol. 2012 Sep 20;12:22. doi: 10.1186/1472-6807-12-22. BMC Struct Biol. 2012. PMID: 22995073 Free PMC article.
Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays.
Goedken ER, Devanarayan V, Harris CM, Dowding LA, Jakway JP, Voss JW, Wishart N, Jordan DC, Talanian RV. Goedken ER, et al. Among authors: talanian rv. J Biomol Screen. 2012 Aug;17(7):857-67. doi: 10.1177/1087057112447108. Epub 2012 May 14. J Biomol Screen. 2012. PMID: 22584786
Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide.
Shahripour AB, Plummer MS, Lunney EA, Sawyer TK, Stankovic CJ, Connolly MK, Rubin JR, Walker NP, Brady KD, Allen HJ, Talanian RV, Wong WW, Humblet C. Shahripour AB, et al. Among authors: talanian rv. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2779-82. doi: 10.1016/s0960-894x(01)00573-x. Bioorg Med Chem Lett. 2001. PMID: 11591522
57 results